title: Effects of 1α,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells.
abstract: BACKGROUND
  There is evidence from epidemiological and in vitro studies that the biological effects of testosterone (T) on cell cycle and survival are modulated by 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) in prostate cancer. To investigate the cross talk between androgen- and vitamin D-mediated intracellular signaling pathways, the individual and combined effects of T and 1,25(OH)2D3 on global gene expression in LNCaP prostate cancer cells were assessed.
  
  
  RESULTS
  Stringent statistical analysis identifies a cohort of genes that lack one or both androgen response elements (AREs) or vitamin D response elements (VDREs) in their promoters, which are nevertheless differentially regulated by both steroids (either additively or synergistically). This suggests that mechanisms in addition to VDR- and AR-mediated transcription are responsible for the modulation of gene expression. Microarray analysis shows that fifteen miRNAs are also differentially regulated by 1,25(OH)2D3 and T. Among these miR-22, miR-29ab, miR-134, miR-1207-5p and miR-371-5p are up regulated, while miR-17 and miR-20a, members of the miR-17/92 cluster are down regulated. A number of genes implicated in cell cycle progression, lipid synthesis and accumulation and calcium homeostasis are among the mRNA targets of these miRNAs. Thus, in addition to their well characterized effects on transcription, mediated by either or both cognate nuclear receptors, 1,25(OH)2D3 and T regulate the steady state mRNA levels by modulating miRNA-mediated mRNA degradation, generating attenuation feedback loops that result in global changes in mRNA and protein levels. Changes in genes involved in calcium homeostasis may have specific clinical importance since the second messenger Ca2+ is known to modulate various cellular processes, including cell proliferation, cell death and cell motility, which affects prostate cancer tumor progression and responsiveness to therapy.
  
  
  CONCLUSIONS
  These data indicate that these two hormones combine to drive a differentiated phenotype, and reinforce the idea that the age dependent decline in both hormones results in the de-differentiation of prostate tumor cells, which results in increased proliferation, motility and invasion common to aggressive tumors. These studies also reinforce the potential importance of miRNAs in prostate cancer progression and therapeutic outcomes.
authors: Department of Biomedical Sciences, University at Albany, State University of New York, Albany, NY 12222, USA.
authors: Wei-Lin W
authors: WL
authors: Wang
authors: Namita
authors: N
authors: Chatterjee
authors: Sridar V
authors: SV
authors: Chittur
authors: JoEllen
authors: J
authors: Welsh
authors: Martin P
authors: MP
authors: Tenniswood
references: Ann Hematol. 2010 Jan;89(1):1-7
references: 19475409
references: BJU Int. 2002 Oct;90(6):607-16
references: 12230626
references: Prostate. 2011 Apr;71(5):538-49
references: 20886540
references: Proc Nutr Soc. 2008 May;67(2):115-27
references: 18412986
references: Eur J Cancer Prev. 2009 Nov;18(6):458-75
references: 19730382
references: Eur J Cancer. 2010 Mar;46(5):932-6
references: 20064705
references: J Biol Chem. 2006 Feb 10;281(6):3731-7
references: 16332683
references: Biochem Biophys Res Commun. 1991 Aug 30;179(1):90-6
references: 1883394
references: Prostate. 2004 May 15;59(3):243-51
references: 15042599
references: BJU Int. 2009 Aug;104(4):438-48
references: 19558559
references: J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):712-6
references: 17280828
references: Endocr Relat Cancer. 2002 Mar;9(1):45-59
references: 11914182
references: Int J Cancer. 2009 Sep 15;125(6):1328-33
references: 19437538
references: PLoS One. 2010 May 12;5(5):e10615
references: 20485546
references: Cancer Res. 2008 Aug 1;68(15):6162-70
references: 18676839
references: Cancer Causes Control. 2010 Aug;21(8):1297-303
references: 20383574
references: BJU Int. 2009 Nov;104(9):1191-7
references: 19624596
references: Mol Endocrinol. 2005 Nov;19(11):2685-95
references: 16002434
references: J Nutr. 2004 Dec;134(12 Suppl):3463S-3471S
references: 15570055
references: Nat Protoc. 2009;4(1):44-57
references: 19131956
references: Ann Epidemiol. 2009 Jul;19(7):468-83
references: 19523595
references: Endocrinology. 1998 Mar;139(3):1197-207
references: 9492054
references: FASEB J. 2010 Feb;24(2):425-35
references: 19805577
references: Nucleic Acids Res. 2011 Mar;39(6):2045-56
references: 21088000
references: Curr Opin Clin Nutr Metab Care. 2007 Jan;10(1):6-11
references: 17143048
references: Clin Cancer Res. 1995 Sep;1(9):997-1003
references: 9816072
references: J Biol Chem. 2004 Dec 17;279(51):53213-21
references: 15485861
references: Cancer Biol Ther. 2008 Aug;7(8):1288-96
references: 18497571
references: J Cell Physiol. 2006 Nov;209(2):363-9
references: 16883603
references: Cell Cycle. 2009 Aug;8(15):2315-6
references: 19625765
references: Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19983-8
references: 18056640
references: Front Neuroendocrinol. 2008 May;29(2):169-81
references: 18093638
references: Biochim Biophys Acta. 2009 Jun;1793(6):1105-9
references: 19339216
references: Cancer Res. 2009 Sep 15;69(18):7165-9
references: 19738047
references: J Mol Endocrinol. 2005 Aug;35(1):117-33
references: 16087726
references: RNA. 2008 Mar;14(3):417-24
references: 18174313
references: J Steroid Biochem Mol Biol. 2010 Jul;121(1-2):368-71
references: 20347977
references: Physiology (Bethesda). 2008 Apr;23:84-94
references: 18400691
references: Biochem Biophys Res Commun. 2009 Jun 5;383(3):280-5
references: 19302977
references: J Steroid Biochem Mol Biol. 2008 Nov;112(1-3):151-6
references: 18938245
references: Prostate. 2011 Jan 1;71(1):98-110
references: 20632309
references: Cancer Res. 2007 Jul 1;67(13):6130-5
references: 17616669
references: J Biol Chem. 2008 Jan 11;283(2):1026-33
references: 17991735
references: Circ Res. 2000 Aug 4;87(3):214-20
references: 10926872
references: J Invest Dermatol. 2010 Jan;130(1):124-34
references: 19759552
references: Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):71-7
references: 14744736
references: Adv Cancer Res. 2010;107:137-62
references: 20399963
references: Cancer Epidemiol. 2009 Dec;33(6):435-45
references: 19939760
references: Nutr Rev. 2007 Aug;65(8 Pt 2):S116-7
references: 17867385
references: J Cell Biochem. 2008 Nov 1;105(4):998-1007
references: 18773415
references: Mol Cancer Ther. 2007 Apr;6(4):1433-9
references: 17431122
references: BJU Int. 2009 Oct;104(7):909-14
references: 19426195
references: Prostate. 2005 Sep 1;64(4):362-72
references: 15754350
references: Methods. 2001 Dec;25(4):402-8
references: 11846609
references: Cancer Cell. 2002 Mar;1(2):169-79
references: 12086875
references: J Natl Cancer Inst. 1997 Feb 5;89(3):182-5
references: 9016994
references: J Clin Endocrinol Metab. 2009 Feb;94(2):418-20
references: 19193916
references: Biol Pharm Bull. 1999 Oct;22(10):1058-63
references: 10549855
references: Clin Cancer Res. 2006 Oct 1;12(19):5895-901
references: 17020998
references: Carcinogenesis. 2006 Sep;27(9):1883-93
references: 16624828
references: J Cell Biochem. 2006 Aug 15;98(6):1450-6
references: 16518840
references: Curr Cancer Drug Targets. 2006 May;6(3):229-44
references: 16712459
references: J Steroid Biochem Mol Biol. 2004 Oct;92(3):131-41
references: 15555907
references: Cell Death Differ. 2002 May;9(5):561-73
references: 11973614
references: J Steroid Biochem Mol Biol. 2002 Dec;83(1-5):85-92
references: 12650704
references: Oncogene. 2010 Sep 2;29(35):4980-8
references: 20562918